Extended Adjuvant

1

Endocrine Adjuvant Therapies New Standards and
New Avenues
The Evolving Chapter of Adjuvant Endocrine
Therapy 9th Milan Breast Cancer Conference June
20-22 2007
Paul E. Goss, MD, PhD, FRCPC,
FRCP(UK)  Professor of Medicine, Harvard Medical
School Director of Breast Cancer Research, MGH
Cancer Center Co-Director of the Breast Cancer
Disease Program, DF/HCC Avon Senior Scholar
HARVARD MEDICAL SCHOOL
2
Innovation and Care in the Next 12
MonthsEndocrine Therapy in Early Stage Breast
Cancer

• BIG 1-98
• LET versus LET to TAM
• TAM to LET versus LET to TAM
• TEAM
• EXE versus TAM
• EXE versus TAM to EXE
• MA17
• Effect By Age
• Delayed extended therapy
• Case Control prognostic predictive factors

3
Innovation and Care in the Next 12
MonthsEndocrine Therapy in Early Stage Breast
Cancer

• Trials of Optimal AIs
• MA27 (EXE versus ANA)
• FACE (LET versus ANA)
• Metastatic Trials
• ANA versus ANA FULVESTRANT
• LET VERSUS LET LAPATINIB in HER2 and HER2-
• Duration of AI Trials
• MA17R
• NSABP B42
• SALSA
• Results of aTTom and ATLAS